-
There is little doubt that cerebrovascular disease is a major contributor to cognitive decline in the elderly. Recurrent symptomatic strokes affecting cortical or subcortical function inevitably result in a stepwise burden of accumulating damage and disability.
-
Confavreux and colleagues studied 1844 multiple sclerosis (MS) patients enrolled in a large European database up until 1997. Clinical variables were identified early in the course of the disease, and their continued prognostic significance was determined after the first stages of irreversible neurological disability.
-
Currently, there are no medications specifically approved in the United States for treatment of the advanced stages of Alzheimers disease (AD). Results of the first US large-scale, prospective, double-blind study of memantine in the treatment of moderate-to-severe AD indicate that memantine-treated advanced AD patients fare better than those who received placebo, with no significant treatment-related side effects.
-
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA).
-
The triptans are 5-hydroxytryptamine (5-HT) 1B/1D receptor agonists. The major use for this class of drugs is for the acute treatment of migraines with or without an aura in adults.
-
Research has indicated that women have risked their health by long-term use of hormone replacement therapy. Now new research says the therapy seems to have little benefit in aiding quality-of-life measures either.
-
In a move that will encourage such programs across the nation, a federal judge has ruled in favor of a Medicaid program that uses preferred drug lists and prior authorization.
-
The bar code proposal of the U.S. Food and Drug Administration isnt the only measure being lauded by the Institute for Safe Medication Practices in Huntingdon Valley, PA. The safety organization also praises two bills recently passed by the U.S. House of Representatives.
-
-
The following drugs are in various stages of clinical studies and trials.